Cardinal Health (CAH) announced a significant expansion of its Actinium-225 production capabilities at the company’s Center for Theranostics Advancement in Indianapolis, Indiana. The addition of a high-capacity production line to its Drug Master File will substantially increase Cardinal Health’s supply of cGMP-compliant Ac-225 for use in investigational therapeutic drug products and future commercial manufacturing novel therapies. Since announcing routine Ac-225 production globally at scale at the end of 2024, Cardinal Health has quadrupled its weekly output. The company expects to continue increasing production capacity in 2026, supporting the rapidly growing global demand for targeted alpha therapies.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- The Week That Was, The Week Ahead: Macro and Markets, Mar. 29
- Cardinal chair Gregory Kenny to retire, Patricia Hemingway Hall to succeed
- Cardinal Health Announces Board Chair Transition and Outlook
- Cardinal Health Announces Planned Chief Accounting Officer Transition
- Cardinal Health price target raised to $258 from $243 at Barclays